Get informed when a big investor buys or sells
+ FollowNovember 5, 2026 - AI Summary
Overvalued by 98.8% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $30.82 Billion |
|---|---|
| Enterprise Value | $33.25 Billion |
| Annual dividend | $1.02 |
| Dividend yield | 1.44% |
| Earnings per Share | $1.25 |
| Beta | 0.62 |
| Outstanding Shares | 469,750,000 |
| P/E Ratio | 40.92 |
|---|---|
| PEG | 111.42 |
| Price to Sales | 7.29 |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | 7.58 |
| Enterprise Value to EBIT | 33.36 |
| Enterprise Value to Net Income | -164 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.26 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends ...